Last reviewed · How we verify
Vinblastine and Sirolimus
Vinblastine and Sirolimus is a Small molecule drug developed by The Hospital for Sick Children. It is currently in Phase 1 development. Also known as: Vinblastine Sulfate Injection, Rapamune.
At a glance
| Generic name | Vinblastine and Sirolimus |
|---|---|
| Also known as | Vinblastine Sulfate Injection, Rapamune |
| Sponsor | The Hospital for Sick Children |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Anemia
- Fatigue
- Generalized muscle weakness
- Infections and infestations - Other, Bacteremia
- Neutrophil count decreased
- Platelet count decreased
- White blood cell decreased
- Febrile Neutropenia
- Dysgeusia
- Gastrointestinal disorders - Other, Hernia
- Hyponatremia
- Thromboembolic event
Key clinical trials
- Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours (PHASE1)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Study of Vinblastine and Sirolimus in Children With Recurrent/Refractory Solid Tumours Including CNS Tumours (PHASE1)
- Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vinblastine and Sirolimus CI brief — competitive landscape report
- Vinblastine and Sirolimus updates RSS · CI watch RSS
- The Hospital for Sick Children portfolio CI
Frequently asked questions about Vinblastine and Sirolimus
What is Vinblastine and Sirolimus?
Vinblastine and Sirolimus is a Small molecule drug developed by The Hospital for Sick Children.
Who makes Vinblastine and Sirolimus?
Vinblastine and Sirolimus is developed by The Hospital for Sick Children (see full The Hospital for Sick Children pipeline at /company/the-hospital-for-sick-children).
Is Vinblastine and Sirolimus also known as anything else?
Vinblastine and Sirolimus is also known as Vinblastine Sulfate Injection, Rapamune.
What development phase is Vinblastine and Sirolimus in?
Vinblastine and Sirolimus is in Phase 1.
What are the side effects of Vinblastine and Sirolimus?
Common side effects of Vinblastine and Sirolimus include Anemia, Fatigue, Generalized muscle weakness, Infections and infestations - Other, Bacteremia, Neutrophil count decreased, Platelet count decreased.
Related
- Manufacturer: The Hospital for Sick Children — full pipeline
- Also known as: Vinblastine Sulfate Injection, Rapamune
- Compare: Vinblastine and Sirolimus vs similar drugs
- Pricing: Vinblastine and Sirolimus cost, discount & access